Profile: Geron Corp (GERN.OQ)
11 Mar 2014
Geron Corporation (Geron), incorporated on November 28, 1990, is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.
The Company generates its revenues from research support payments under collaboration agreements and milestones, royalties and other revenues from its licensing arrangements. The Company operates in one segment, the discovery and development of therapeutic products for oncology.
SUITE 2070, 149 COMMONWEALTH DRI
MENLO PARK CA 94025